Redburn Atlantic analyst Jamie Clark initiated coverage of Quest Diagnostics (DGX) with a Buy rating and $195 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Steady Growth and Strategic Advancements Justify Buy Rating
- Quest Diagnostics: Resilient Investment with Strategic Growth Initiatives and Strong Financials
- Quest Diagnostics price target raised to $191 from $190 at Baird
- Quest Diagnostics: Stable Long-Term Growth Prospects and Strategic Market Positioning
- Quest Diagnostics Unveils Growth Strategy at Investor Day